Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled Phase II Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for Multiple Sclerosis

NCT06715605 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT06715605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06715605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled Phase II Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for Multiple Sclerosis
Lead sponsor
University Hospital, Antwerp
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2025
Completion date
October 29, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis